Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 7Gynecologic 6Genitourinary 2Breast 2Thoracic 1

Conditions

Prostatic Neoplasms 2Ovarian Neoplasms 2Breast Neoplasms 2

Interventions

Docetaxel 409pembrolizumab 332Prednisone 290enzalutamide 285Gemcitabine 274Radiotherapy 270Magnetic Resonance Spectroscopy 269Nivolumab 253Abiraterone Acetate 218Cisplatin 212Leuprolide 195Radiosurgery 192Sunitinib 188Carboplatin 161Androgen Antagonists 156bicalutamide 152Specimen Handling 149Goserelin 149Ipilimumab 131Paclitaxel 126acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 122apalutamide 118Cyclophosphamide 117Bevacizumab 116Sorafenib 114Everolimus 111abiraterone 108cabozantinib 105atezolizumab 105Biopsy 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
senaparib × Genitourinary × Clear all
NCT03507543 2021-03-30

The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors

Impact Therapeutics, Inc.

Phase 1 Completed
39 enrolled
BreastGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms

NCT03508011 2021-03-30

A Study of IMP4297 in Patients With Advanced Solid Tumors

Impact Therapeutics, Inc.

Phase 1 Completed
57 enrolled
BreastGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡